These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 33598693)

  • 1. Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin.
    Schmalbrock LK; Dolnik A; Cocciardi S; Sträng E; Theis F; Jahn N; Panina E; Blätte TJ; Herzig J; Skambraks S; Rücker FG; Gaidzik VI; Paschka P; Fiedler W; Salih HR; Wulf G; Schroeder T; Lübbert M; Schlenk RF; Thol F; Heuser M; Larson RA; Ganser A; Stunnenberg HG; Minucci S; Stone RM; Bloomfield CD; Döhner H; Döhner K; Bullinger L
    Blood; 2021 Jun; 137(22):3093-3104. PubMed ID: 33598693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.
    Stone RM; Mandrekar SJ; Sanford BL; Laumann K; Geyer S; Bloomfield CD; Thiede C; Prior TW; Döhner K; Marcucci G; Lo-Coco F; Klisovic RB; Wei A; Sierra J; Sanz MA; Brandwein JM; de Witte T; Niederwieser D; Appelbaum FR; Medeiros BC; Tallman MS; Krauter J; Schlenk RF; Ganser A; Serve H; Ehninger G; Amadori S; Larson RA; Döhner H
    N Engl J Med; 2017 Aug; 377(5):454-464. PubMed ID: 28644114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2- and FLT3-inhibitors in the treatment of
    Seipel K; Marques MAT; Sidler C; Mueller BU; Pabst T
    Haematologica; 2018 Nov; 103(11):1862-1872. PubMed ID: 29976747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
    Shoukier M; Kadia T; Konopleva M; Alotaibi AS; Alfayez M; Loghavi S; Patel KP; Kanagal-Shamanna R; Cortes J; Samra B; Jabbour E; Garcia-Manero G; Takahashi K; Pierce S; Short NJ; Yilmaz M; Sasaki K; Masarova L; Pemmaraju N; Borthakur G; Kantarjian HM; Ravandi F; DiNardo CD; Daver N
    Cancer; 2021 Feb; 127(3):381-390. PubMed ID: 33119202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midostaurin in combination with chemotherapy is most effective in patients with acute myeloid leukemia presenting with high FLT3-ITD allelic ratio who proceed to allogeneic stem cell transplantation while in first complete remission.
    Ofran Y; Leiba R; Frisch A; Horesh N; Henig I; Yehudai-Ofir D; Moshe Y; Neaman M; Ganzel C; Gal-Rabinovich K; Hellmann I; Weinstein V; Berger T; Wolach O
    Eur J Haematol; 2021 Jan; 106(1):64-71. PubMed ID: 32949053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
    Döhner H; Weber D; Krzykalla J; Fiedler W; Wulf G; Salih H; Lübbert M; Kühn MWM; Schroeder T; Salwender H; Götze K; Westermann J; Fransecky L; Mayer K; Hertenstein B; Ringhoffer M; Tischler HJ; Machherndl-Spandl S; Schrade A; Paschka P; Gaidzik VI; Theis F; Thol F; Heuser M; Schlenk RF; Bullinger L; Saadati M; Benner A; Larson R; Stone R; Döhner K; Ganser A
    Blood Adv; 2022 Sep; 6(18):5345-5355. PubMed ID: 35486475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.
    Luskin MR; DeAngelo DJ
    Expert Rev Hematol; 2017 Dec; 10(12):1033-1045. PubMed ID: 29069942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia.
    Sasaki K; Kantarjian HM; Kadia T; Patel K; Loghavi S; Garcia-Manero G; Jabbour EJ; DiNardo C; Pemmaraju N; Daver N; Dalle IA; Short N; Yilmaz M; Bose P; Naqvi K; Pierce S; Yalniz F; Cortes JE; Ravandi F
    Cancer; 2019 Nov; 125(21):3755-3766. PubMed ID: 31310323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
    Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
    Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.
    Williams CB; Kambhampati S; Fiskus W; Wick J; Dutreix C; Ganguly S; Aljitawi O; Reyes R; Fleming A; Abhyankar S; Bhalla KN; McGuirk JP
    Pharmacotherapy; 2013 Dec; 33(12):1341-52. PubMed ID: 23798029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells.
    Djamai H; Berrou J; Dupont M; Kaci A; Ehlert JE; Weber H; Baruchel A; Paublant F; Prudent R; Gardin C; Dombret H; Braun T
    Leuk Res; 2021 Jan; 100():106490. PubMed ID: 33373830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of FLT3 Internal Tandem Duplications in Adult Syrian Patients with Acute Myeloid Leukemia and Normal Karyotype.
    Al-Arbeed IF; Wafa A; Moassass F; Al-Halabi B; Al-Achkar W; Abou-Khamis I
    Asian Pac J Cancer Prev; 2021 Oct; 22(10):3245-3251. PubMed ID: 34711001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.